REFERENCES

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence,
and future trends. Lancet. 2007 Sep 1;370(9589):765-73.

2. Raherison C, Girodet PO. Epidemiology of COPD. Eur Respir Rev. 2009

Dec;18(114):213-21.

3. Chabot F, Gomez E, Guillaumot A, Kheir A, Chaouat A. [Acute

exacerbations of chronic obstructive pulmonary disease]. Presse Med.
2009 Mar;38(3):485-95.

4. Soler-Cataluna JJ, Sanchez-Sanchez L, Martinez-Garcia MA, Sanchez PR,

Salcedo E, Navarro M. Mid-arm muscle area is a better predictor of
mortality than body mass index in COPD. Chest. 2005 Oct;128(4):2108-
15.

5. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary

disease: phenomenon or epiphenomenon? Proc Am Thorac Soc.
2004;1(2):109-14.

6. Global Initiative for chronic obstructive Lung Disease. Global Strategy

for the Diagnosis,Management and Prevention of Chronic Obstructive
Pulmonary Disease:NHLBI/WHO Workshop Report.National Institute of
Health;2001. NIH Publication No.2701 Available at
http://www.goldcopd.com

7. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic

value in chronic obstructive pulmonary disease? Am J Respir Crit Care
Med.
2002 Aug 1;166(3):329-32.

8. Burchfiel CM, Marcus EB, Curb JD, Maclean CJ, Vollmer WM, Johnson LR,
et al. Effects of smoking and smoking cessation on longitudinal decline
in pulmonary function. Am J Respir Crit Care Med. 1995
Jun;151(6):1778-85.

9. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB,

Vessey RS, et al. C-reactive protein in patients with COPD, control
smokers and non-smokers. Thorax. 2006 Jan;61(1):23-8.

10. Orvoen-Frija E, Benoit M, Catto M, Chambouleyron M, Duguet A,

Emeriau JP, et al. [Chronic obstructive pulmonary disease (COPD) in the
elderly]. Rev Mal Respir. 2010 Oct;27(8):855-73.

11. Piquet J, Chavaillon JM, David P, Martin F, Braun D, Ferrer Lopez P,

et al. [Characteristics and management of acute exacerbations of
COPD in hospital. EABPCO-CPHG study by the college of general
hospital respiratory physicians]. Rev Mal Respir. 2010;27(1):19-29.

12. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones
PW, et al. Effect of pharmacotherapy on rate of decline of lung function
in chronic obstructive pulmonary disease: results from the TORCH
study. Am J Respir Crit Care Med. 2008 Aug 15;178(4):332-8.
 13. Corhay JL, Louis R. [Clinical study of the month: the TORCH study
(TOwards a Revolution in COPD Health)]. Rev Med Liege. 2007
Apr;62(4):230-4.

14 Roche N, Zureik M, Soussan D, Neukirch F, Perrotin D, Urgence BSC.

Predictors of outcomes in COPD exacerbation cases presenting to the
emergency department. Eur Respir J. 2008 Oct;32(4):953-61.

15. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role
of comorbidities. Eur Respir J. 2006 Dec;28(6):1245-57.

16. Mahouachi R, Belhadjhassine A, Chtourou A, Haouari D, Neji

R,Hammouda F, et al. Décompensations aigues des BPCO, à propos de
63 cas. Rev Mal Respir.

2008 april;32(7):63-9. Publication en ligne : 17 avril 2008.

17. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-
van Molken MP. The impact of aging and smoking on the future burden
of chronic obstructive pulmonary disease: a model analysis in the
Netherlands. Am J Respir Crit Care Med. 2001 Aug 15;164(4):590-6.

18. BPCO EN-REdAdPad, Federation Francaise des Associations et Amicales

d'Insuffisants R. [Chronic obstructive pulmonary disease: an overview].
Rev Mal Respir. 2003 Jun;20(3 Pt 1):471-6.

19. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et
al. Salmeterol and fluticasone propionate and survival in chronic
obstructive pulmonary disease. N Engl J Med. 2007 Feb 22;356(8):775-
89.
 20. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, et al.
Effect of tiotropium on outcomes in patients with moderate chronic
obstructive pulmonary disease (UPLIFT): a prespecified subgroup
analysis of a randomised controlled trial. Lancet. 2009 Oct
3;374(9696):1171-8.

21. Buist AS. The US Lung Health Study. Respirology. 1997 Dec;2(4):303-7.

22. Crockett AJ, Cranston JM, Moss JR, Alpers JH. A review of long-term
oxygen therapy for chronic obstructive pulmonary disease. Respir Med.

2001 Jun;95(6):437-43.

23. Tillie-Leblond I, Housset B. [Debates surrounding COPD]. Rev Mal

Respir. 2010 Feb;27(2):106-7.

24. Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized
assignment to a smoking cessation intervention and changes in
smoking habits on respiratory symptoms in smokers with early chronic
obstructive pulmonary disease: the Lung Health Study. Am J Med. 1999
Apr;106(4):410-6.

25. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM,

Soriano JB. The natural history of chronic airflow obstruction revisited:
an analysis of the Framingham offspring cohort. Am J Respir Crit Care
Med. 2009 Jul 1;180(1):3-10.
 26. Bourdin A, Burgel PR, Chanez P, Garcia G, Perez T, Roche N. Recent
advances in COPD: pathophysiology, respiratory physiology and clinical
aspects, including comorbidities. Eur Respir Rev. 2009
Dec;18(114):198-212.

27. Burgel PR. Rôle des comorbidités dans l’évolution de la BPCO. Rev Mal
Resp. 2008;25:11-15.

28. Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level
and its clinical impact in a cohort of patients with COPD. Eur Respir J.

2007 May;29(5):923-9.

29. Mannino DM, Shorr AF, Doyle JJ, Stern LS, Dolgister M, Siegartel LR, et
al. Prevalence of anemia in subjects with chronic obstructive pulmonary
disease. Proc Am Thorac Soc. 2006;3:A615.

30. Chambellan A, Chailleux E, Similowski T, Group AO. Prognostic value of

the hematocrit in patients with severe COPD receiving long-term
oxygen therapy. Chest. 2005 Sep;128(3):1201-8.

31. Dowson C, Laing R, Barraclough R, Town I, Mulder R, Norris K, et al. The

use of the Hospital Anxiety and Depression Scale (HADS) in patients
with chronic obstructive pulmonary disease: a pilot study. N Z Med J.

2001 Oct 12;114(1141):447-9.

32. Dowson CA, Kuijer RG, Mulder RT. Anxiety and self-management
behaviour in chronic obstructive pulmonary disease: what has been
learned? Chron Respir Dis. 2004;1(4):213-20.
 33. Hynninen KM, Breitve MH, Wiborg AB, Pallesen S, Nordhus IH.
Psychological characteristics of patients with chronic obstructive
pulmonary disease: a review. J Psychosom Res. 2005 Dec;59(6):429-43.

34. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined

comorbidity index. J Clin Epidemiol. 1994 Nov;47(11):1245-51.

35. Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S,

Heredia JL, et al. Mortality after hospitalization for COPD. Chest. 2002
May;121(5):1441-8.

36. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E,

Navarro M, Ochando R. Severe acute exacerbations and mortality in
patients with chronic obstructive pulmonary disease. Thorax. 2005
Nov;60(11):925-31.

37. Marti S, Munoz X, Rios J, Morell F, Ferrer J. Body weight and comorbidity
predict mortality in COPD patients treated with oxygen therapy. Eur
Respir J.

2006 Apr;27(4):689-96.

38. Casanova C, Cote C, Marin JM, Pinto-Plata V, de Torres JP, Aguirre-Jaime

A, et al. Distance and oxygen desaturation during the 6-min walk test
as predictors of long-term mortality in patients with COPD. Chest. 2008
Oct;134(4):746-52.
 39. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA, Committee
TCE. Ascertainment of cause-specific mortality in COPD: operations of
the TORCH Clinical Endpoint Committee. Thorax. 2007 May;62(5):411-
5.

40. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett
JE, et al. The effects of a smoking cessation intervention on 14.5-year
mortality: a randomized clinical trial. Ann Intern Med. 2005 Feb
15;142(4):233-9.

41. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary
disease at increased risk of cardiovascular diseases? The potential role
of systemic inflammation in chronic obstructive pulmonary disease.
Circulation.

2003 Mar 25;107(11):1514-9.

42. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, et al.
Inhaled corticosteroids and mortality in chronic obstructive pulmonary
disease. Thorax. 2005 Dec;60(12):992-7.

43. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A,

Charpentier C, et al. Prognostic factors in COPD patients receiving long-
term oxygen therapy. Importance of pulmonary artery pressure. Chest.
1995 May;107(5):1193-8.

44. Ai-Ping C, Lee KH, Lim TK. In-hospital and 5-year mortality of patients
treated in the ICU for acute exacerbation of COPD: a retrospective
study. Chest.

2005 Aug;128(2):518-24.
 45. Pison CM1, Cano NJ, Chérion C, Caron F, Court-Fortune I, Antonini MT,
et al. Multimodal nutritional rehabilitation improves clinical outcomes of
malnourished patients with chronic respiratory failure: a randomised
controlled trial. Thorax.

2011 Nov;66(11):953-60.

46. Chailleux E, Laaban JP, Veale D. Prognostic value of nutritional

depletion in patients with COPD treated by long-term oxygen therapy:
data from the ANTADIR observatory. Chest. 2003 May;123(5):1460-6.

47. Cano NJ, Pichard C, Roth H, Court-Fortune I, Cynober L, Gerard-

Boncompain M, et al. C-reactive protein and body mass index predict
outcome in end-stage respiratory failure. Chest. 2004 Aug;126(2):540-
6.

48. Hallin R, Gudmundsson G, Suppli Ulrik C, Nieminen MM, Gislason T,

Lindberg E, et al. Nutritional status and long-term mortality in
hospitalised patients with chronic obstructive pulmonary disease
(COPD). Respir Med. 2007 Sep;101(9):1954-60.

49. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of

nutritional status in chronic obstructive pulmonary disease.

Am J Respir Crit Care Med. 1999 Dec;160(6):1856-61.

50. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible
factor in the prognosis of chronic obstructive pulmonary disease.

Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1791-7.

51. Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, et
al. Body mass, fat-free body mass, and prognosis in patients with
chronic obstructive pulmonary disease from a random population
sample: findings from the Copenhagen City Heart Study. Am J Respir
Crit Care Med. 2006 Jan 1;173(1):79-83.

52. Nizet TA, van den Elshout FJ, Heijdra YF, van de Ven MJ, Mulder PG,
Folgering HT. Survival of chronic hypercapnic COPD patients is
predicted by smoking habits, comorbidity, and hypoxemia. Chest. 2005
Jun;127(6):1904-10.

53. Hallin R, Koivisto-Hursti UK, Lindberg E, Janson C. Nutritional status,

dietary energy intake and the risk of exacerbations in patients with
chronic obstructive pulmonary disease (COPD). Respir Med. 2006
Mar;100(3):561-7.

54. Fiatarone MA, O'Neill EF, Ryan ND, Clements KM, Solares GR, Nelson
ME, et al. Exercise training and nutritional supplementation for physical
frailty in very elderly people. N Engl J Med. 1994 Jun 23;330(25):1769-
75.

55. Foley RJ, ZuWallack R. The impact of nutritional depletion in chronic

obstructive pulmonary disease. J Cardiopulm Rehabil. 2001 Sep-
Oct;21(5):288-95.

56. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter

M, et al. Canadian Thoracic Society recommendations for management
of chronic obstructive pulmonary disease - 2007 update. Can Respir J.
2007 Sep;14 Suppl B:5B-32B.

57. Société de Pneumologie de Langue F. [Updated guidelines of the

 Societe de Pneumologie de Langue Francaise for the management of
chronic obstructive pulmonary disease: essential points]. Rev Mal
Respir. 2003 Apr;20(2 Pt 1):294-9.

58. National Collaborating Centre for Chronic C. Chronic obstructive

pulmonary disease. National clinical guideline on management of
chronic obstructive pulmonary disease in adults in primary and
secondary care. Thorax.

2004 Feb;59 Suppl 1:1-232.

59. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br

Med J. 1977 Jun 25;1(6077):1645-8.

60. Domingo-Salvany A, Lamarca R, Ferrer M, Garcia-Aymerich J, Alonso J,

Felez M, et al. Health-related quality of life and mortality in male
patients with chronic obstructive pulmonary disease. Am J Respir Crit
Care Med.

2002 Sep 1;166(5):680-5.

61. Celli BR, Cote CG, Lareau SC, Meek PM. Predictors of Survival in COPD:
more than just the FEV1. Respir Med. 2008 Jun;102 Suppl 1:S27-35.

62. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor

of 5-year survival than airway obstruction in patients with COPD. Chest.

2002 May;121(5):1434-40.

63. Saydain G, Beck KC, Decker PA, Cowl CT, Scanlon PD. Clinical
significance of elevated diffusing capacity. Chest. 2004 Feb;125(2):446-
52.
 64. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete
measure of health status for chronic airflow limitation. The St. George's
Respiratory Questionnaire. Am Rev Respir Dis. 1992 Jun;145(6):1321-7.

65. Meguro M, Barley EA, Spencer S, Jones PW. Development and

Validation of an Improved, COPD-Specific Version of the St. George
Respiratory Questionnaire. Chest. 2007 Aug;132(2):456-6

66. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, et
al. Health-related quality of life in patients by COPD severity within
primary care in Europe. Respir Med. 2011 Jan;105(1):57-66.

67. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise
intolerance in chronic obstructive pulmonary disease. Am J Respir Crit
Care Med. 2001 Sep 1;164(5):770-7.

68. Marin JM, Carrizo SJ, Casanova C, Martinez-Camblor P, Soriano JB,

Agusti AG, et al. Prediction of risk of COPD exacerbations by the BODE
index. Respir Med.

2009 Mar;103(3):373-8.

69. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et

al. Susceptibility to exacerbation in chronic obstructive pulmonary
disease.

N Engl J Med. 2010 Sep 16;363(12):1128-38.

70. Jones PW, Agusti AG. Outcomes and markers in the assessment of
chronic obstructive pulmonary disease. Eur Respir J. 2006
Apr;27(4):822-32.
 71. McKellar A, Cottrell WN, Whelan A. BODE score is a useful predictor of
hospital admission in rural patients with chronic obstructive pulmonary
disease. Respirology. 2008 May;13(3):438-43.

72. Faganello MM, Tanni SE, Sanchez FF, Pelegrino NR, Lucheta PA, Godoy
I. BODE index and GOLD staging as predictors of 1-year exacerbation
risk in chronic obstructive pulmonary disease. Am J Med Sci. 2010
Jan;339(1):10-4.

73. Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Anto JM, Agusti AG, et
al. Expansion of the prognostic assessment of patients with chronic
obstructive pulmonary disease: the updated BODE index and the ADO
index. Lancet.

2009 Aug 29;374(9691):704-11.

74. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R.

Characteristics of physical activities in daily life in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med. 2005 May 1;171(9):972-
7.

75. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular

physical activity reduces hospital admission and mortality in chronic
obstructive pulmonary disease: a population based cohort study.
Thorax. 2006 Sep;61(9):772-8.

76. Couillard A, Prefaut C. From muscle disuse to myopathy in COPD:

potential contribution of oxidative stress. Eur Respir J. 2005
Oct;26(4):703-19.
 77. Abdel Kafi S, Deboeck G. [Question 3-7. Six minute walking test in
respiratory therapy]. Rev Mal Respir. 2005 Nov;22(5 Pt 3):7S54-7S8.

78. Cote CG, Pinto-Plata V, Kasprzyk K, Dordelly LJ, Celli BR. The 6-min walk
distance, peak oxygen uptake, and mortality in COPD. Chest.

2007 Dec;132(6):1778-85.

79. Cote CG, Casanova C, Marin JM, Lopez MV, Pinto-Plata V, de Oca MM, et
al. Validation and comparison of reference equations for the 6-min walk
distance test. Eur Respir J. 2008 Mar;31(3):571-8.

80. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients

with COPD. Eur Respir J. 2009 Feb;33(2):262-72.

81. Quon BS, Gan WQ, Sin DD. Contemporary management of acute
exacerbations of COPD: a systematic review and metaanalysis. Chest.
2008 Mar;133(3):756-66

82. Fournier M, Tonnel AB, Housset B, Huchon G, Godard P, Vervloet D, et

al. [Economic burden of COPD: the SCOPE study]. Rev Mal Respir.

2005 Apr;22(2 Pt 1):247-55

83. Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM,
Wedzicha JA. Longitudinal changes in the nature, severity and
frequency of COPD exacerbations. Eur Respir J. 2003 Dec;22(6):931-6.

84. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing
 exacerbations on deterioration of health status in COPD. Eur Respir J.
2004 May;23(5):698-702.

85. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez
FJ, et al. Roflumilast in symptomatic chronic obstructive pulmonary
disease: two randomised clinical trials. Lancet. 2009 Aug
29;374(9691):685-94.

86. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M,
Martinez FJ, et al. Roflumilast in moderate-to-severe chronic obstructive
pulmonary disease treated with longacting bronchodilators: two
randomised clinical trials. Lancet.

2009 Aug 29;374(9691):695-703.

87. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ,
Bredenbroker D, et al. Reduction in sputum neutrophil and eosinophil
numbers by the PDE4 inhibitor roflumilast in patients with COPD.
Thorax. 2007 Dec;62(12):1081-7.

88. Cuvelier A. Exacerbations des BPCO: le temps passé, les conceptions

doivent évoluer. Rev Mal Respir. 2003 Nov;20:23-31.

89. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA.
Time course and recovery of exacerbations in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med. 2000
May;161(5):1608-13.
 90. Roche N, Zureik M, Neukirch F, Perrotin D, study Ce. [The "COPD
emergency 2003" study: a description of the hospital management of
exacerbations of COPD]. Rev Mal Respir. 2004 Feb;21(1):117-22.

91. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship

between exacerbation frequency and lung function decline in chronic
obstructive pulmonary disease. Thorax. 2002 Oct;57(10):847-52.

92. Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation
to tobacco dependence of chronic obstructive pulmonary disease in a
nationally representative population sample. Thorax. 2006
Dec;61(12):1043-7.

93. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al.
Chronic obstructive pulmonary disease phenotypes: the future of
COPD.

Am J Respir Crit Care Med. 2010 Sep 1;182(5):598-604.

94. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-

year trial of tiotropium in chronic obstructive pulmonary disease. N
Engl J Med.

2008 Oct 9;359(15):1543-54.

95. Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulbas G, Pehlivan E, et

al. Factors affecting survival of hospitalised patients with COPD. Eur
Respir J. 2005 Aug;26(2):234-41.

96. Bach PB, Brown C, Gelfand SE, McCrory DC, American College of
Physicians- American Society of Internal M, American College of Chest
 P. Management of acute exacerbations of chronic obstructive
pulmonary disease: a summary and appraisal of published evidence.
Ann intern Med. 2001 Apr 3;134(7):600-20.

97. Wang Q1, Bourbeau J. Outcomes and health-related quality of

life following hospitalization for an acute exacerbation of COPD. Respirology.

2005 Jun;10(3):334-40.

98. Garcia-Aymerich J1, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis
KJ. Lung function impairment, COPD hospitalisations and subsequent
mortality. Thorax. 2011 Jul;66(7):585-90.

99. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive

factors of hospitalization for acute exacerbation in a series of 64
patients with chronic obstructive pulmonary disease. Am J Respir Crit
Care Med. 1999 Jan;159(1):158-64.

100. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P,

Caramori G, et al. Infections and airway inflammation in chronic
obstructive pulmonary disease severe exacerbations. Am J Respir Crit
Care Med. 2006 May 15;173(10):1114-21.

101. Murphy TF, Sethi S. Bacterial infection in chronic obstructive

pulmonary disease. Am Rev Respir Dis. 1992 Oct;146(4):1067-83.

102. Agence francaise de securite sanitaire des produits de santé.

[Antibiotic therapy in general and current practice in lower respiratory
tract infections in adults and children. Recommendations]. Med Mal
Infect. 2005 Dec;35(12):619-34.
 103. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson
G, Message S, et al. Respiratory viruses, symptoms, and
inflammatory markers in acute exacerbations and stable chronic
obstructive pulmonary disease.

Am J Respir Crit Care Med. 2001 Nov 1;164(9):1618-23.

104. Sethi S. Bacteria in exacerbations of chronic obstructive

pulmonary disease: phenomenon or epiphenomenon? Proc Am
Thorac Soc. 2004;1(2):109-14.

105. Sethi S, Murphy TF. Infection in the pathogenesis and course of

chronic obstructive pulmonary disease. N Engl J Med. 2008 Nov
27;359(22):2355-65.

106. Chermiti Ben Abdallah F, Fereh Y, Ben Hadj Hssine A,

Mahouachi R, Chtourou A, Taktak S, et al. Exacerbations aiguës de
BPCO : rôle de la surinfection bactérienne. Rev Mal Respir.
2012;29(Suppl.1):A174.

107. Yang X, Strobel M, Tian L, Barennes H, Buisson Y. [Bacterial

flora in acute exacerbations of chronic obstructive pulmonary
disease (COPD) in Kunming, China]. Med Mal Infect. 2011
Apr;41(4):186-91.

108. Alamoudi OS. Bacterial infection and risk factors in outpatients

with acute exacerbation of chronic obstructive pulmonary disease: a
2-year prospective study. Respirology. 2007 Mar;12(2):283-7.

109. Boussaid H, Rouetbi N, Cheikh Mhamed S, Agina S,

Gharsellaoui Z, Benzarti W, et al. Les exacerbations aiguës
infectieuses de BPCO. Relation entre le profil bactériologique et la
sévérité de la maladie. Rev Mal Respir. 2013;30:A37-A38.